VALN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

VA

Volume

9.36K

Next Earnings

November 19th

Loading chart

VA

VALNValneva SE American Depositary Shares

VALN

Pay with—

Available Balance0.00

VA

Mkt Cap

$560.4M

Volume

9.36K

Next Earnings

November 19th

Chart Earnings News About Insider Filings

Why Pfizer Stock Was so Healthy in AugustPfizer stock surged nearly 14% in August following better-than-expected Q2 earnings (revenue $15B vs. $14.4B expected, EPS $0.77 vs. $0.68 expected) and raised full-year revenue guidance. The company also achieved regulatory victories with EMA validation for a Lyme disease treatment and FDA approval for an updated COVID vaccine. Despite investor impatience over the lack of new blockbuster products, the analyst views Pfizer as undervalued with a promising pipeline from recent acquisitions.The Motley Fool · Sep 8, 2026

VALNEVA : Déclaration d’actions et de droits de vote - Statut au 31 mai 2026Valneva SE reported Q1 2026 financial results with total product sales of €30.5 million and a cash position of €105.3 million as of end March 2026, excluding proceeds from a successful reserved offering completed in April 2026. The company announced participation in U.S. and European investor conferences in June 2026.GlobeNewswire Inc. · Jun 3, 2026

VALNEVA:Declaration of shares and voting rights - Status as of May 31, 2026Valneva SE reported its share capital composition as of May 31, 2026, with 189.77 million ordinary shares and double voting rights on 1,859 shares. The company also announced Q1 2026 financial results showing product sales of €30.5 million and a cash position of €105.3 million as of end March 2026, excluding proceeds from an April reserved offering.GlobeNewswire Inc. · Jun 3, 2026

Déclaration d'actions et de droits de vote de la société Valneva SE - Mars 2026Pfizer and Valneva announced that their Lyme disease vaccine candidate PF-07307405 (LB6V) demonstrated over 70% efficacy in preventing Lyme disease in individuals aged five years and older in Phase 3 VALOR trial. The vaccine candidate was well-tolerated.GlobeNewswire Inc. · Apr 3, 2026

Declaration of shares and voting rights of Valneva SE – March 2026Pfizer and Valneva announced that their Lyme disease vaccine candidate PF-07307405 (LB6V) demonstrated over 70% efficacy in preventing Lyme disease in people aged five years and older during Phase 3 VALOR trial. The companies also announced Valneva's participation in the 26th World Vaccine Congress in Washington DC.GlobeNewswire Inc. · Apr 3, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALNPomerantz LLP is investigating potential securities fraud claims against Valneva SE and partner Pfizer following the failure of their Phase 3 Lyme disease vaccine candidate (LB6V) to meet its primary endpoint. The announcement triggered a sharp 37.11% decline in Valneva's ADR price on March 23, 2026.GlobeNewswire Inc. · Mar 24, 2026

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path AliveValneva and Pfizer's Phase 3 VALOR trial for their Lyme disease vaccine failed to meet its primary endpoint due to fewer cases being accrued than expected. However, secondary analyses showed clinically meaningful efficacy of 73-75%, and Pfizer plans to proceed with regulatory submissions. Valneva shares fell 35.27% on the news, trading significantly below key moving averages.Benzinga · Mar 23, 2026

VALNEVA Déclaration d’actions et de droits de vote : 31 janvier 2026Valneva has voluntarily withdrawn its IXCHIQ chikungunya vaccine BLA (Biologics License Application) and IND (Investigational New Drug) in the United States. The company is continuing to review global product opportunities based on medical need and commercial attractiveness. This decision comes as Valneva and Instituto Butantan announced initiation of a pilot vaccination campaign in Brazil with the single-shot vaccine.GlobeNewswire Inc. · Feb 6, 2026

VALNEVA Declaration of shares and voting rights: January 31, 2026Valneva has voluntarily withdrawn its Biologics License Application (BLA) and Investigational New Drug (IND) for IXCHIQ chikungunya vaccine in the United States. Simultaneously, the company is advancing a pilot vaccination campaign with Instituto Butantan in Brazil, continuing to evaluate the global product opportunity based on medical need and commercial attractiveness.GlobeNewswire Inc. · Feb 6, 2026

VALNEVA Déclaration d’actions et de droits de vote : 30 novembre 2025Valneva is consolidating its French operations at its Lyon site and finalizing R&D consolidation in Vienna. The company also reported positive Phase 2 results for its Lyme Disease vaccine candidate, showing sustained antibody levels and no safety concerns.GlobeNewswire Inc. · Dec 5, 2025

to start trading

VA

VALNValneva SE American Depositary Shares

VALN

Pay with—

Available Balance0.00

Your PositionYou don't own any VALN yet.

Related Tickers

Earnings